SurModics Inc (SRDX) - Total Liabilities

Latest as of June 2025: $58.51 Million USD

Based on the latest financial reports, SurModics Inc (SRDX) has total liabilities worth $58.51 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SRDX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

SurModics Inc - Total Liabilities Trend (1998–2024)

This chart illustrates how SurModics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of SurModics Inc.

SurModics Inc Competitors by Total Liabilities

The table below lists competitors of SurModics Inc ranked by their total liabilities.

Company Country Total Liabilities
Grid Dynamics Holdings Inc
NASDAQ:GDYN
USA $80.44 Million
Svolder AB (publ)
ST:SVOL-B
Sweden Skr109.50 Million
Alpha Tau Medical Ltd
NASDAQ:DRTS
USA $27.11 Million
India Tourism Development Corporation Limited
NSE:ITDC
India Rs3.51 Billion
CytomX Therapeutics Inc
NASDAQ:CTMX
USA $79.16 Million
MarineMax Inc
NYSE:HZO
USA $1.48 Billion
Arvind Fashions Limited
NSE:ARVINDFASN
India Rs30.55 Billion
Wuxi Xuelang Environmental Technology Co Ltd
SHE:300385
China CN¥2.02 Billion

Liability Composition Analysis (1998–2024)

This chart breaks down SurModics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SRDX equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.91 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.53 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.34 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SurModics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SurModics Inc (1998–2024)

The table below shows the annual total liabilities of SurModics Inc from 1998 to 2024.

Year Total Liabilities Change
2024-09-30 $59.66 Million -9.36%
2023-09-30 $65.82 Million +31.73%
2022-09-30 $49.97 Million -8.33%
2021-09-30 $54.51 Million +44.55%
2020-09-30 $37.71 Million +0.96%
2019-09-30 $37.35 Million -32.73%
2018-09-30 $55.52 Million +121.78%
2017-09-30 $25.04 Million -3.93%
2016-09-30 $26.06 Million +281.18%
2015-09-30 $6.84 Million +11.39%
2014-09-30 $6.14 Million -24.28%
2013-09-30 $8.11 Million -11.65%
2012-09-30 $9.18 Million -47.02%
2011-09-30 $17.32 Million +8.78%
2010-09-30 $15.92 Million +20.70%
2009-09-30 $13.19 Million -73.20%
2008-09-30 $49.22 Million +21.81%
2007-09-30 $40.41 Million +231.25%
2006-09-30 $12.20 Million +41.13%
2005-09-30 $8.64 Million -43.42%
2004-09-30 $15.28 Million +30.64%
2003-09-30 $11.69 Million +61.23%
2002-09-30 $7.25 Million +48.54%
2001-09-30 $4.88 Million +99.63%
2000-09-30 $2.45 Million +6.35%
1999-09-30 $2.30 Million +43.75%
1998-09-30 $1.60 Million --

About SurModics Inc

NASDAQ:SRDX USA Medical Devices
Market Cap
$614.51 Million
Market Cap Rank
#11255 Global
#2920 in USA
Share Price
$42.98
Change (1 day)
+0.35%
52-Week Range
$26.42 - $42.98
All Time High
$80.35
About

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision o… Read more